NDA 019071 · Mission Pharma
Urocit-K
Potassium Citrate · Oral
Priority reviewOrphanLast checked: Nov 20, 2026Latest source record: Dec 10, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1985
Aug 30, 1985
Approved uses
1
Original approval plus efficacy supplements
Registered trials
90
16 Phase 3, 5 recruiting
FAERS reports
5,569
3,307 serious, 320 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 16, 2025.
1 INDICATIONS AND USAGE 1.1 Renal Tubular Acidosis (RTA) with Calcium Stones Potassium Citrate is indicated for the management of renal tubular acidosis [see Clinical Studies (14.1)]. 1.2 Hypocitraturic Calcium Oxalate Nephrolithiasis of any Etiology Potassium Citrate is indicated for the management of Hypocitraturic calcium oxalate nephrolithiasis [see Clinical Studies (14.2)]. 1.3 Uric Acid Lithiasis with or without Calcium Stones Potassium Citrate is indicated for the management of Uric acid lithiasis with or without calcium stones [see Clinical Studies (14.3)]. Potassium Citrate is a citrate salt of potassium indicated for the management of: Renal tubular acidosis (RTA) with calcium stones (1.1) Hypocitraturic calcium oxalate nephrolithiasis of any etiology (1.2) Uric acid lithiasis with or without calcium stones (1.3)
Mechanism: When Potassium Citrate is given orally, the metabolism of absorbed citrate produces an alkaline load. The induced alkaline load in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate. Thus, Potassium Citrate therapy appears to increase urinary citrate principally by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. The increased filtered load of citrate may play some role, however, as in small comparisons of oral citrate and oral bicarbonate, citrate had a...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 30, 1985 Original approval · Type 3 - New Dosage Form · priority review
3 products under this application
- UROCIT-K · POTASSIUM CITRATE 10MEQ · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- UROCIT-K · POTASSIUM CITRATE 15MEQ · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- UROCIT-K · POTASSIUM CITRATE 5MEQ · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Urocit-K" as an intervention, any sponsor and status, largest first.
- Helicobacter Pylori Eradication and Follow-upStatus unknown
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT05061732 · 4,447 participants (planned) · Start Sep 30, 2021 · Primary completion Jun 30, 2026
Drug: Rabeprazole; Bismuth potassium citrate and 7 more · For: Helicobacter Pylori Infection
Sites: Shanghai, China
- A Study on the Effection of Potassium Citrate Extended-release Tablets on Urolithiasis Formation or RecurrencePivotal-lookingStatus unknown
Dawnrays Pharmaceutical (Holdings) LimitedIndustry
NCT03007160 · 2,001 participants (planned) · Start Jul 2016 · Primary completion Sep 2020
Drug: Potassium Citrate Extended-release Tablets · For: Urolithiasis
Sites: Guangzhou, China; Zhengzhou, China; Wuhan, China · 6 sites in all
- Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 DaysPivotal-lookingStatus unknown
Shandong UniversityAcademic, hospital or other
NCT04901117 · 1,300 participants (planned) · Start Jun 2021 · Primary completion Jun 2023
Drug: Amoxicillin; Clarithromycin and 5 more · For: Helicobacter Pylori Infection
Sites: Jinan, China
- Bismuth-containing Quadruple Therapy for Helicobacter Pylori EradicationPivotal-lookingCompleted
Shandong UniversityAcademic, hospital or other
NCT05049902 · 1,300 participants · Start Sep 21, 2021 · Primary completion May 30, 2023
Drug: Amoxicillin; Clarithromycin and 5 more · For: Helicobacter Pylori Infection
Sites: Nanjing, China; Dezhou, China; Heze, China · 6 sites in all
- PPI-amoxicillin for H. Pylori TreatmentPivotal-lookingStatus unknown
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT05014685 · 732 participants (planned) · Start Aug 20, 2021 · Primary completion Dec 30, 2022
Drug: Rabeprazole; Bismuth potassium citrate and 2 more · For: Helicobacter Pylori Infection
Sites: Shanghai, China
- Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori InfectionPivotal-lookingCompleted
TenNor Therapeutics (Suzhou) LimitedIndustry
NCT05857163 · 700 participants · Start May 18, 2023 · Primary completion Dec 24, 2023
Drug: Rifasutenizol capsules; Rabeprazole sodium enteric-coated tablets and 6 more · For: H.Pylori Infection
Sites: Beijing, China
- The Evaluation of Triple Therapy With Vonoprazan, Amoxicillin and Bismuth for Eradication of Helicobacter PyloriPivotal-lookingStatus unknown
Huazhong University of Science and TechnologyAcademic, hospital or other
NCT05189444 · 672 participants (planned) · Start Mar 25, 2022 · Primary completion Dec 31, 2022
Drug: Vonoprazan; Amoxicillin and 4 more · For: Helicobacter Pylori Infection
Sites: Wuhan, China
- Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled TrialPivotal-lookingCompleted
Zhongshan Hospital (Xiamen), Fudan UniversityAcademic, hospital or other
NCT06977841 · 640 participants · Start Jun 10, 2025 · Primary completion Mar 10, 2026
Drug: Tegoprazan; Amoxicillin and 2 more · For: Helicobacter Pylori Eradication; Adverse Reaction
Sites: Xiamen, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective462
- fatigue378
- nausea340
- diarrhoea339
- pain309
- nephrolithiasis279
- off label use271
- dizziness248
- dyspnoea229
- headache217
- fall207
- vomiting186
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 16 |
| 2005 | 17 |
| 2006 | 26 |
| 2007 | 34 |
| 2008 | 35 |
| 2009 | 57 |
| 2010 | 78 |
| 2011 | 104 |
| 2012 | 112 |
| 2013 | 123 |
| 2014 | 145 |
| 2015 | 290 |
| 2016 | 365 |
| 2017 | 326 |
| 2018 | 374 |
| 2019 | 373 |
| 2020 | 409 |
| 2021 | 449 |
| 2022 | 516 |
| 2023 | 450 |
| 2024 | 446 |
| 2025 | 484 |
| 2026 | 340 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Urocit-K (Potassium Citrate)
2024 spending
$95K
Beneficiaries
78
274 claims
Per beneficiary
$1,212
$2.28 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $256,481 |
| 2021 | $196,461 |
| 2022 | $146,317 |
| 2023 | $112,862 |
| 2024 | $94,509 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of potassium-magnesium citrate on upper gastrointestinal mucosa.
Gonzalez GB, Pak CY, Adams-Huet B, et al. · Aliment Pharmacol Ther 1998 · Clinical Trial, Comparative Study
- [Clinical study of Urocit-K: a slow releasing potassium citrate].
Hwang TI, Yang CR, Lai LH · Zhonghua Yi Xue Za Zhi (Taipei) 1992 · Clinical Trial, English Abstract
Sponsor: Mission Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.